Starling Oncology/$STLN
1D1W1MYTD1Y5YMAX
Capital at risk
About Starling Oncology
Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
- Ticker
- $STLN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 641
- Headquarters
- Cerritos, United States
- Website
- starlingoncology.com
STLN Metrics
BasicAdvanced
$679M
-
-$0.30
0.44
-
Price and volume
Market cap
$679M
Beta
0.44
52-week high
$7.13
52-week low
$2.32
Average daily volume
1.3M
Financial strength
Current ratio
1.359
Quick ratio
1.135
Long term debt to equity
-3.904
Total debt to equity
-4.206
Interest coverage (TTM)
-3.42%
Profitability
EBITDA (TTM)
-19.281
Gross margin (TTM)
15.69%
Net profit margin (TTM)
-6.18%
Operating margin (TTM)
-4.44%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-9.65%
Return on equity (TTM)
214.12%
Valuation
Price to revenue (TTM)
1.145
Price to book
-26.86
Price to tangible book (TTM)
-16.03
Price to free cash flow (TTM)
-204.709
Free cash flow yield (TTM)
-0.49%
Free cash flow per share (TTM)
-0.033
Growth
Revenue change (TTM)
38.38%
Earnings per share change (TTM)
-54.81%
3-year revenue growth (CAGR)
26.11%
3-year earnings per share growth (CAGR)
-30.64%
Bulls say / Bears say
Q2 showed strong operating momentum: revenue rose 34.6% year over year to $161.3 million, gross profit increased 55.2% to $27.2 million, and adjusted EBITDA turned positive; management consequently raised 2026 revenue and gross-profit guidance. (Starling Oncology)
Starling expanded its value-based growth platform by adding approximately 230,000 capitated lives through California exclusivity and signing its first delegated contracts outside Florida in Nevada and Oregon; management expects about $150 million of capitated revenue in 2026. (Starling Oncology)
The August launch of Starling Nexus could improve provider engagement, pathway adherence, and authorization efficiency by combining oncology decision support with utilization management, while creating a foundation for pharmacy and clinical-trial integration. (Starling Oncology)
Starling remains GAAP-unprofitable: Q2 net loss was $9.8 million, while cash and equivalents were $41.1 million at June 30, 2026; the quarter’s adjusted EBITDA was only $229,000. (Starling Oncology)
The business remains highly sensitive to medical-cost execution: management forecasts a 80%–90% medical loss ratio over the next 12 months and only $2–$7 million of adjusted EBITDA on $650–$670 million of 2026 revenue. (Starling Oncology)
A director and 10% owner sold 298,853 shares at a weighted-average price of $6.5126 on August 21, 2026; although the Form 4 indicates a Rule 10b5-1 plan, the transaction may still create a near-term overhang on investor sentiment. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing STLN
Fund name | Fund size | $STLN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.